<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842491</url>
  </required_header>
  <id_info>
    <org_study_id>ENDOCX</org_study_id>
    <nct_id>NCT00842491</nct_id>
  </id_info>
  <brief_title>Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Endostar (Recombinant Human Endostatin ®) With Cisplatin and Capecitabine (Xeloda) as 1st Line Treatment in the Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiansheng Pharmaceutical Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether endostar (recombinant human&#xD;
      endostatin)with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced&#xD;
      gastric cancer is effective and safe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endostar, a recombinant human endostatin, has shown its antitumor ability in combination in&#xD;
      NSCLC and breast cancer. But to gastric cancer, few clinical data has been reported. However,&#xD;
      bevacizumab, an angiogenesis inhibitor was shown effective in combination with chemotherapy&#xD;
      in advanced gastric cancer in some phase II study. So in this study, we want to explore&#xD;
      whether endostar is also effective and safe in advanced gastric cancer. Response predictive&#xD;
      factor is expected to be identified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse evens</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The alteration of relative regional blood volume of the tumor</measure>
    <time_frame>3weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>endostar+chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endostar, cisplatin, capecitabine</intervention_name>
    <description>Product 1: endostar&#xD;
Dosing schedule: 15mg daily dose, d1-14&#xD;
Mode of administration: intravenously</description>
    <arm_group_label>endostar+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Product 2: capecitabine&#xD;
Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks&#xD;
Mode of administration: orally</description>
    <arm_group_label>endostar+chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Product 3: cisplatin&#xD;
Dosing schedule: 80mg/m2, day 1 of every 3 weeks&#xD;
Mode of administration: intravenously</description>
    <arm_group_label>endostar+chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Having signed informed consent&#xD;
&#xD;
          -  Age 18 to 70 years old&#xD;
&#xD;
          -  Histologically confirmed gastric adenocarcinoma&#xD;
&#xD;
          -  Unresectable recurrent or metastatic disease&#xD;
&#xD;
          -  Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more&#xD;
             than 6 months&#xD;
&#xD;
          -  Previous chemotherapy with capecitabine or cisplatin, if applicable, more than 12&#xD;
             months.&#xD;
&#xD;
          -  Measurable disease according to the RECIST criteria&#xD;
&#xD;
          -  Karnofsky performance status ≥60&#xD;
&#xD;
          -  Life expectancy of ≥2 month&#xD;
&#xD;
          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than&#xD;
             4 weeks&#xD;
&#xD;
          -  ALT and AST&lt;2.5 times ULN (≤5 times ULN in patients with liver metastases)&#xD;
&#xD;
          -  Serum albumin level ≥3.0g/dL&#xD;
&#xD;
          -  Serum AKP &lt; 2.5 times ULN&#xD;
&#xD;
          -  Serum creatinine &lt;ULN, and CCr &lt; 60ml/min&#xD;
&#xD;
          -  Bilirubin level &lt; 1.5 ULN&#xD;
&#xD;
          -  WBC&gt;3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3, Hb&gt;9g/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Brain metastasis (known or suspected)&#xD;
&#xD;
          -  Previous systemic therapy for metastatic gastric cancer&#xD;
&#xD;
          -  Inability to take oral medication&#xD;
&#xD;
          -  Previous therapy targeting at angiogenesis or vasculogenesis pathway or other targeted&#xD;
             therapy&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry&#xD;
&#xD;
          -  Contraindications of nuclear magnetic resonance image such as fitment of cardiac&#xD;
             pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball&#xD;
             and so on.&#xD;
&#xD;
          -  Allergic constitution or allergic history to protium biologic product or any&#xD;
             investigating agents.&#xD;
&#xD;
          -  Severe heart disease or such history as recorded congestive heart failure,&#xD;
             uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve&#xD;
             disease, severe abnormal ECG findings, cardiac infarction , or retractable&#xD;
             hypertension.&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Any investigational agent within the past 28 days&#xD;
&#xD;
          -  Other previous malignancy within 5 year, except non-melanoma skin cancer&#xD;
&#xD;
          -  Previous adjuvant therapy with capecitabine+platinum,&#xD;
&#xD;
          -  Pre-existing neuropathy&gt;grade 1&#xD;
&#xD;
          -  Legal incapacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lin shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University, School of oncology, Department of GI oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of GI Oncology, Peking University, School of Oncology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>February 11, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>pro.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

